Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells
Robert E. Hunger, Peter A. Sieling, Maria Teresa Ochoa, Makoto Sugaya, Anne E. Burdick, Thomas H. Rea, Patrick J. Brennan, John T. Belisle, Andrew Blauvelt, Steven A. Porcelli, Robert L. Modlin
Robert E. Hunger, Peter A. Sieling, Maria Teresa Ochoa, Makoto Sugaya, Anne E. Burdick, Thomas H. Rea, Patrick J. Brennan, John T. Belisle, Andrew Blauvelt, Steven A. Porcelli, Robert L. Modlin
View: Text | PDF
Article Dermatology

Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells

  • Text
  • PDF
Abstract

Langerhans cells (LCs) constitute a subset of DCs that initiate immune responses in skin. Using leprosy as a model, we investigated whether expression of CD1a and langerin, an LC-specific C-type lectin, imparts a specific functional role to LCs. LC-like DCs and freshly isolated epidermal LCs presented nonpeptide antigens of Mycobacterium leprae to T cell clones derived from a leprosy patient in a CD1a-restricted and langerin-dependent manner. LC-like DCs were more efficient at CD1a-restricted antigen presentation than monocyte-derived DCs. LCs in leprosy lesions coexpress CD1a and langerin, placing LCs in position to efficiently present a subset of antigens to T cells as part of the host response to human infectious disease.

Authors

Robert E. Hunger, Peter A. Sieling, Maria Teresa Ochoa, Makoto Sugaya, Anne E. Burdick, Thomas H. Rea, Patrick J. Brennan, John T. Belisle, Andrew Blauvelt, Steven A. Porcelli, Robert L. Modlin

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Specificity of the proliferative responses of CD1a-restricted T cell clo...
Specificity of the proliferative responses of CD1a-restricted T cell clones to different bacterial lysates and known CD1-restricted antigens. (A) T cell lines were tested for their ability to recognize different total bacterial sonicates. M. tb., M. tuberculosis. (B) M. leprae sonicate preparation was digested with proteinase K. The proliferative response was determined using CD1a-restricted T cell line B2.1, B2.11 and the MHC class II–restricted cell line C10E. Inact. prot. K indicates that the enzyme was heat-inactivated prior to adding to bacterial extract. (C) Proliferative response was measured using different known CD1b- and CD1c-restricted antigens. Proliferative responses were measured as described for Figure 2 using LC-like DCs as APCs for T cell clones B2.1 and B2.11 and MHC-matched PBMCs for the C10E T cell line. PIM, phosphatidyl-myo-inositol mannoside; LAM, lipoarabinomannan; LM, lipomannan; GMM, glucose monomycolate; MPI, mannosyl phosphoisoprenoid. (D) Characterization of mycobacterial antigen for CD1a-restricted T cells. Left: CD1a-restricted T cell clone B2.11 was cultured with three mycobacterial extracts containing cytosol (CYT), membrane (MEM), soluble cell wall material (CWS), and mycolyl arabinogalactin peptidoglycan (MAGP). Total ext., mycobacterial extract prior to fractionation. Right: T cell–responsive MAGP was examined for CD1a-restriction using neutralizing antibodies to CD1a. The values shown are the mean ± SEM of triplicate cultures and are representative of at least three independent experiments. Statistical analysis was performed as indicated in the legend to Figure 2, but comparing T cells stimulated with media versus antigen. *P < 0.05; **P < 0.005.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts